南京江北新区铁路小学
该站暂未设置description...
该站暂未设置keywords...
百度权重
百度移动
360权重
搜狗权重
站点URL: http://www.pktlxx.cn · 站点编号:286549 · 加入时间:2025-07-11 15:57:18
做上本站友情链接,在您站上点击一次,即可自动秒收录并自动排在本站第一位!<a href="http://w8t.2dhz.cn/" target="_blank">吾爱导航收录站</a>
站点预估流量 | 百度来访IP:- | 移动端来访IP:- | 出站链接:76 | 站内链接:4 |
IP地址与网速 | IP地址:- 地址:- | 网速:317毫秒 |
ALEXA 排 名 | 世界排名:- | 预估IP:- | 预估PV:- |
域名备案信息 | - | 名称:- | 已创建:未知 |
收录 | 百度 | 360 | 搜狗 | 谷歌 |
查询 | 0 | 0 | 0 | 0 |
电脑关键词 | 手机关键词 | 页面友好 | 首页位置 | 索引 | 近期收录 |
0 | 0 | 电脑端优秀 | - | 0 | 0 |
服务器信息 协议类型 HTTP/1.1 200 OK 页面类型 text/html; charset=utf-8 服务器类型 nginx 程序支持 连接标识 消息发送 2025年5月30日 18时26分44秒 GZIP检测 已启用GZIP压缩 源文件大小 39.83KB 压缩后大小 12.51KB 压缩率 68.59% |
域名(www.pktlxx.cn)由网友主动性提交被吾爱导航收录站整理收录的,本页最后更新时间为:2025-07-11 15:57:19,吾爱导航收录站仅提供www.pktlxx.cn的基础信息并免费向广大游客展示,该站IP地址为- 地址:-,该站打开速度为317毫秒,该站的百度权重为0、百度手机权重为0、百度收录为0条、360收录为0条、搜狗收录为0条、谷歌收录为0条、百度来访流量大约在-之间、百度手机端来访流量大约在-之间、www.pktlxx.cn的备案号是-、备案人叫-、被百度收录的关键词有0个、手机端关键词有0个、迄今为止已经创建未知,其内容不代表本站赞成被显示该站点的内容或立场,相关资料: txt下载、docx下载、pdf下载、rar下载、zip下载,本页地址:http://w8t.2dhz.cn/links/8b4919d54925f187030d.html。
WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity,foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.